Pralsetinib clinical trials
Also written Gavreto® and BLU-667.
How each study uses pralsetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pralsetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 4 Sept 2020 · GAVRETO · NDA 213721 (FDA, Drugs@FDA)
- European Union
- 18 Nov 2021 · Gavreto · EMEA/H/C/005413 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
Hoffmann-La Roche (4) · Genentech, Inc. (2) · Fujian Medical University (1) · Rigel Pharmaceuticals (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Alectinib (3) · Entrectinib (3) · Atezolizumab (3) · Divarasib (2) · Ipatasertib (2) · Ado-Trastuzumab Emtansine (2) · Inavolisib (2) · Dabrafenib (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test pralsetinib.
- Nov 2026A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2 · Genentech, Inc.
- Jul 2027Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsPhase 4 · Rigel Pharmaceuticals
- Nov 2027Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses pralsetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 4Rigel PharmaceuticalsNCT07704658Written as Pralsetinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Pralsetinib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Pralsetinib
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Genentech, Inc.NCT04302025Written as Pralsetinib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Pralsetinib
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 3Hoffmann-La RocheNCT04222972Written as Pralsetinib
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedPhase 1/2Hoffmann-La RocheNCT03037385Written as pralsetinib (BLU-667)
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992Written as Pralsetinib
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnPhase 3Hoffmann-La RocheNCT04760288Written as Pralsetinib
Given beside what is tested · 3 — pralsetinib is usual care or a partner of the new treatment
- A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLCNot yet recruitingNot applicableFudan UniversityNCT07418879Written as Pralsetinib
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Pralsetinib
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431Written as Pralsetinib
Codes
What other systems call pralsetinib · ClinicalTrials.gg INT001228
- MeSH (NLM) C000655704pralsetinibOne source ClinicalTrials.gov
- UNII (FDA) 1WPE73O1WVPRALSETINIBConfirmed FDA, Wikidata
- RxNorm 2394936One source FDA
- Wikidata Q97732199pralsetinibConfirmed FDA, Wikidata
- NCI Thesaurus C132295PralsetinibOne source FDA
- DrugBank DB15822One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000655704 | pralsetinib | One source ClinicalTrials.gov |
| UNII (FDA) | 1WPE73O1WV | PRALSETINIB | Confirmed FDA, Wikidata |
| RxNorm | 2394936 | — | One source FDA |
| Wikidata | Q97732199 | pralsetinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C132295 | Pralsetinib | One source FDA |
| DrugBank | DB15822 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.